GCG and type 2 diabetes mellitus: Linagliptin (LGP) is a class of DPP-4 (Dipeptidyl peptidase-4) inhibitor with a unique pharmacokinetic (PK) profile, characterized by negligible renal excretion, and used in the treatment of type II diabetes as glucagon increases blood glucose levels, while DPP-4 inhibitors reduce glucagon and blood glucose levels.